Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, Lim JK, Darling J, Pockros P, Galati JS, Frazier LM, Alqahtani S, Sulkowski MS, Vainorius M, Akushevich L, Fried MW, Zeuzem S; HCV-TARGET Study Group. Welzel TM, et al. Among authors: pockros p. Gut. 2017 Oct;66(10):1844-1852. doi: 10.1136/gutjnl-2016-311609. Epub 2016 Jul 13. Gut. 2017. PMID: 27418632 Free PMC article.
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, Purdum PP 3rd, Jensen D, Smith C, Lee WM, Boyer TD, Lin A, Pedder S, DePamphilis J. Reddy KR, et al. Among authors: pockros pj. Hepatology. 2001 Feb;33(2):433-8. doi: 10.1053/jhep.2001.21747. Hepatology. 2001. PMID: 11172346 Clinical Trial.
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Hadziyannis SJ, et al. Among authors: pockros pj. Ann Intern Med. 2004 Mar 2;140(5):346-55. doi: 10.7326/0003-4819-140-5-200403020-00010. Ann Intern Med. 2004. PMID: 14996676 Clinical Trial.
Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial.
Pockros PJ, Carithers R, Desmond P, Dhumeaux D, Fried MW, Marcellin P, Shiffman ML, Minuk G, Reddy KR, Reindollar RW, Lin A, Brunda MJ; PEGASYS International Study Group. Pockros PJ, et al. Am J Gastroenterol. 2004 Jul;99(7):1298-305. doi: 10.1111/j.1572-0241.2004.30306.x. Am J Gastroenterol. 2004. PMID: 15233669 Clinical Trial.
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.
Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, Farci P, Gitlin N, O'Brien CB, Lamour F, Lardelli P; PEGASYS Study NR16071 Investigator Group. Zeuzem S, et al. Among authors: pockros p. Gastroenterology. 2004 Dec;127(6):1724-32. doi: 10.1053/j.gastro.2004.09.050. Gastroenterology. 2004. PMID: 15578510 Clinical Trial.
Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.
Arora S, O'Brien C, Zeuzem S, Shiffman ML, Diago M, Tran A, Pockros PJ, Reindollar RW, Gane E, Patel K, Wintfeld N, Green J. Arora S, et al. J Gastroenterol Hepatol. 2006 Feb;21(2):406-12. doi: 10.1111/j.1440-1746.2005.04059.x. J Gastroenterol Hepatol. 2006. PMID: 16509866 Clinical Trial.
174 results